Skip to content
DataLookout
Menu

NCT07781631

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the Blood

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Site details revised
  2. Notable Recruitment opened
    • Eligibility criteria expanded, about 9 words
    • Site details revised
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Timeframe: Up to 40 days.
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Timeframe: Up to 40 days.

Secondary (1)

Minimum concentration of the analyte in plasma at steady state within a uniform dosing interval τ (Cmin,ss)

Arms and interventions

Verducatib, then verducatib + carbamazepineExperimental

Fixed-sequence treatment for all trial participants.

Drugs: Verducatib, Carbamazepine

Sites

1 site in 1 country

  • CRS Clinical Research Services Berlin GmbHBerlin, Germany